
Clinical Scenario: CELMoD Selection After CAR T-Cell and Bispecific Antibody Therapy in Multiple Myeloma
In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss a clinical scenario involving a 68-year-old patient with multiple myeloma who has received all three major drug classes, CAR T-cell therapy with a response lasting approximately one year, and subsequent BCMA-targeted bispecific antibody therapy, followed by disease progression.
Episodes in this series

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss a clinical scenario involving a 68-year-old patient with multiple myeloma who has received all three major drug classes, CAR T-cell therapy with a response lasting approximately one year, and subsequent BCMA-targeted bispecific antibody therapy, followed by disease progression. Dr. Goldsmith considers whether T-cell dysfunction or exhaustion may have contributed to resistance to both T-cell-redirecting therapies, while acknowledging that this mechanism has not been clinically established. He discusses the rationale for considering treatments with direct antimyeloma activity that may also support T-cell fitness, potentially preserving options for future immune-based therapies. Potential approaches include mezigdomide-containing regimens, such as combinations with carfilzomib and dexamethasone, and investigational CELMoD strategies being evaluated in patients previously treated with CAR T-cell and bispecific antibody therapies. The discussion highlights the importance of sequencing treatments strategically in multiple myeloma and the need for continued clinical evidence to clarify how CELMoDs may influence T-cell function and subsequent treatment options.
Related to this article








